Resverlogix Corp RVXCF

Primary Symbol: T.RVX

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

<< Previous

Bullboard Posts

Next >>

Post by fuzzyjron Nov 17, 2024 12:58pm

63 Views

Post# 36317169

TSX s

Short Positions for RVX

Symbol	Report Date	Volume	Change	Shares Issued	% Float
T : RVX	2024-10-31	105,601	44,586	278,000,194	0.04
T : RVX	2024-10-15	61,015	-110,480	278,000,194	0.02
T : RVX	2024-09-30	171,495	98,229	277,700,194	0.06
T : RVX	2024-09-15	73,266	-45,498	276,619,094	0.03
T : RVX	2024-08-31	118,764	24,328	276,619,094	0.04
T : RVX	2024-08-15	94,436	6,651	276,619,094	0.03
T : RVX	2024-07-31	87,785	-3,059	275,183,027	0.03
T : RVX	2024-07-15	90,844	-5,354	275,183,027	0.03
T : RVX	2024-06-30	96,198	4,486	275,183,027	0.03
T : RVX	2024-06-15	91,712	-8,064	275,183,027	0.03